807 / 1266
Medulloblastoma: the (near) future
Patients will be stratified for
treatment on the basis of biological
markers
Low risk: reduce therapy
→
reduce risks
associated with treatment
High risk: intensify treatment/use novel
treatment approaches
Possibility of developing agents that
would target specific molecular
aberrations